Industry news that matters to you.  Learn more

Archives for December 2011

C-Path and The Hamner Announce Collaboration To Improve Safety of Medical Product Development

Critical Path Institute (C-Path) and The Hamner Institutes for Health Sciences (The Hamner) announced today that they have signed a Memorandum of Understanding (MOU) to develop innovative, collaborative activities in the areas of regulatory science research for predicting, detecting and monitoring liver safety issues during the development of new medicines.

European Patent Office Grants Metabolon Patent for Determining Metabolic Age of an Individual

Metabolon, Inc., a diagnostics and services company offering the industry’s leading biochemical profiling technology, announced today the grant of EP Patent 2,089,539B entitled, “Biomarkers Related to Metabolic Age and Methods Using the Same.” The European Patent Office awarded the patent to Metabolon on December 7, 2011 and is the first patent issued to Metabolon by the EPO. The newly issued patent extends Metabolon’s intellectual property (IP) related to biomarkers of metabolic age; US7,781,160, the related United States Patent, was issued by the United States Patent and Trademark Office in August 2010.

NUS Partners with FIND to Discover Novel Biomarkers for Tuberculosis Detection

A research team from the National University of Singapore (NUS) Singapore Lipidomics Incubator (SLING) is collaborating with the Foundation for Innovative New Diagnostics (FIND) to identify novel target molecules to be employed as biomarkers for the detection of active tuberculosis (TB). The aim is to translate these targets into a diagnostic test that is affordable, easy to use and produces rapid results, and that can be used by community health workers in poor countries.

Vermillion Completes the Acquisition of Correlogic Systems’ Ovarian Cancer Diagnostics Business

Vermillion, Inc., a leading molecular diagnostics company, has completed the purchase of substantially all of the assets associated with the ovarian cancer diagnostics business of Correlogic Systems, Inc. for $435,000 in cash.

FDA Clears Critical Diagnostics Presage ST2 Assay for Patients with Heart Failure

Critical Diagnostics is a U.S.-based biomarker company focused on optimizing patient care in cardiovascular diseases, such as heart failure. The San Diego-based company announced yesterday that they have received FDA approval for their Presage ST2 Assay for use as an aid in assessing the prognosis of patients diagnosed with chronic heart failure [1].